Audalis 100 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

audalis 100 mg

medice arzneimittel pütter gmbh & co kg - atomoksetinhydroklorid - tablett, filmdrasjert - 100 mg

Ozawade ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

ozawade

bioprojet pharma - pitolisant - sleep apnea, obstructive - andre nervesystemet narkotika - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).

Atomoxetine Medical Valley 10 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

atomoxetine medical valley 10 mg

medical valley invest ab - atomoksetinhydroklorid - kapsel, hard - 10 mg

Atomoxetine Medical Valley 18 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

atomoxetine medical valley 18 mg

medical valley invest ab - atomoksetinhydroklorid - kapsel, hard - 18 mg

Atomoxetine Medical Valley 25 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

atomoxetine medical valley 25 mg

medical valley invest ab - atomoksetinhydroklorid - kapsel, hard - 25 mg

Atomoxetine Medical Valley 40 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

atomoxetine medical valley 40 mg

medical valley invest ab - atomoksetinhydroklorid - kapsel, hard - 40 mg

Atomoxetine Medical Valley 60 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

atomoxetine medical valley 60 mg

medical valley invest ab - atomoksetinhydroklorid - kapsel, hard - 60 mg

Atomoxetine Medical Valley 80 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

atomoxetine medical valley 80 mg

medical valley invest ab - atomoksetinhydroklorid - kapsel, hard - 80 mg

Atomoxetine Medical Valley 100 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

atomoxetine medical valley 100 mg

medical valley invest ab - atomoksetinhydroklorid - kapsel, hard - 100 mg

Xtandi ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamide - prostata neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.